STATE OF DIFFERENT LINKS OF HORMONAL-METABOLIC CHANGES IN PATIENTS WITH METABOLIC SYNDROME AND OBESITY

2021 ◽  
Vol 17 (78) ◽  
pp. 110
Author(s):  
K. M. Mylytsya ◽  
I. G. Biriuk ◽  
A. S. Lavryk ◽  
M. M. Mylytsya ◽  
K. V. Shepitko
Nutrients ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 319
Author(s):  
Oliver D. John ◽  
Peter Mouatt ◽  
Sunil K. Panchal ◽  
Lindsay Brown

The pulp of the purple mangosteen, Garcinia mangostana, is a popular tropical fruit but the rind containing xanthones such as α-mangostin together with procyanidins and anthocyanidins is usually discarded as waste. However, this rind has been used in South-East Asia for diarrhoea, dysentery, skin infections and wounds. As xanthones have reported anti-inflammatory and antioxidant responses, this study has determined the bioactive compounds and evaluated the effects of G. mangostana rind on physiological, metabolic, liver and cardiovascular parameters in rats with diet-induced metabolic syndrome. Rats fed a diet with increased simple sugars and saturated fats developed obesity, hypertension, increased left ventricular stiffness, dyslipidaemia and fatty liver. Administration of G. mangostana rind as 5% of the food to rats with diet-induced metabolic syndrome gave a dose of 168 mg/kg/day α-mangostin, 355 mg/kg/day procyanidins, 3.9 mg/kg/day anthocyanins and 11.8 mg/kg/day hydroxycitric acid for 8 weeks which reduced body weight and attenuated physiological and metabolic changes in rats including decreased abdominal fat deposition, decreased abdominal circumference and whole-body fat mass, improved liver structure and function and improved cardiovascular parameters such as systolic blood pressure, left ventricular stiffness and endothelial function. These responses were associated with decreased infiltration of inflammatory cells, decreased deposition of collagen in both heart and liver and decreased mean adipocyte size in retroperitoneal adipose tissues. We conclude that, in rats with diet-induced metabolic syndrome, chronic intake of G. mangostana rind decreased infiltration of inflammatory cells which decreased physiological, metabolic, liver and cardiovascular symptoms.


2015 ◽  
Vol 194 (6) ◽  
pp. 1787-1796 ◽  
Author(s):  
Kazumi Taguchi ◽  
Atsushi Okada ◽  
Shuzo Hamamoto ◽  
Shoichiro Iwatsuki ◽  
Taku Naiki ◽  
...  

2012 ◽  
Vol 142 (6) ◽  
pp. 1026-1032 ◽  
Author(s):  
Sunil K. Panchal ◽  
Hemant Poudyal ◽  
Lindsay Brown

2015 ◽  
Vol 14 ◽  
pp. 163-173 ◽  
Author(s):  
Ying-Jie Chen ◽  
Yuan-Hao Lo ◽  
Yi-Ting Chen ◽  
Nai-Wei Lai ◽  
Nan-Hei Lin ◽  
...  

Author(s):  
Kh. I. Kurylo ◽  
A. S. Volska ◽  
I. M. Klishch ◽  
B. V. Zablotskyi

Diabetes mellitus is caused by one of the largest medical and social problems in Ukraine, because it causes a high risk of invasive disease. According to the WHO data, the number of patients is rising and people of varying age groups become ill, which causes an increase in the incidence of 3 to 4 pauses and the overall life expectancy of 20-30%. Pathogenesis of diabetes mellitus and enclosure, require the extraction of drugs for prophylaxis and treatment with late pharmacological effects. One of these is a herbal remedy. Analysis and systematization of the literature on metabolitotropic effects and substantiation of the use of new goat's-rue, blueberry and taurine phytocompositions for the correction of metabolic changes in diabetes type 2 were carried out. The methods of information search, analysis of literature on the medicinal plants with hypoglycemic action were used. The literary resources on pharmacological correction of metabolic changes in diabetes type 2 deal with natural herbs and amino acids that possess hypoglycemic action and can be used with therapeutic and prophylactic measure in patients with type 2 diabetes. In type 2 diabetes mellitus significant anticytolytic, detoxifying and antioxidant properties of phytocompositions were confirmed. It is known that in hyperglycemia and insulin resistance that occur at type 2 diabetes mellitus end products of glycosylation and glucose autooxidation are formed, which is accompanied by the activation of lipid peroxidation and the formation of a large number of free radicals. It is known that one of the basic mechanisms for the development of insulin resistance, diabetes mellitus and specific diabetic angiopathies is oxidative stress. One of the major pathogenetic factors in the development and course of type 2 diabetes mellitus is metabolic syndrome. It has been established that correction using both investigated phytocompositions and reference phytopreparation with different efficiency prevented the development of metabolic changes in metabolic syndrome. Biologically active components of medicinal plants, may show hypoglycemic effect which will influence the activity of the enzymes, glucose transcription and the function of the peptide to the incyline, the processes which play an important role in the pathogenesis of diabetes.


2021 ◽  
Vol 23 (4) ◽  
pp. 717-724
Author(s):  
V. A. Aleksandrov ◽  
L. N. Shilova ◽  
A. V. Aleksandrov ◽  
N. V. Aleksandrova ◽  
I. A. Zborovskaya

Rheumatoid arthritis (RA) is a frequent background for the development of renal pathology. Chronic kidney disease (CKD) is determined in more than 30% of patients with RA. Along with inflammation and other factors in the progression of the underlying disease, the development of renal damage in RA is facilitated by the presence of metabolic syndrome (MetS).The aim of this study is to assess the relationship of serum concentrations of angiopoietin-like proteins (ANGPTL) and antiphospholipid antibodies (aPL) with the development of renal dysfunction in patients with RA.We examined 158 patients with RA (91.8% – women and 8.2% – men) aged 21 to 80 years old and an average duration of the disease – 9 (4-15) years. The majority of patients were seropositive for rheumatoid factor and for antibodies to cyclic citrullinated peptide, with an advanced clinical stage and moderate activity (3.2 < DAS28 ≤ 5.1) of the pathological process.The ELISA test was used for the quantitative determination of angiopoietin-like protein type 3 and type 4 and antibodies to phospholipids (aРL-IgG/IgM) for total detection of antibodies to cardiolipin, phosphatidylserine, phosphatidylinositol, phosphatidylic acid and a complex of negatively charged phospholipid and β2-glycoprotein-I.More than half of the examined RA patients had the calculated glomerular filtration rate (eGFR) ranging from 89 to 60 ml/min/1.73 m2 (allocation by CKD stages: C1 – 21.5%; C2 – 58.9%; C3 – 19.6%). Signs of MetS (a combination of increased blood pressure, increased triglyceride levels and carbohydrate metabolism disorders against the background of central obesity) were diagnosed in 68 (43%) RA patients. Multivariable analysis of variance was performed to compare the studied parameters (ANGPTL3, ANGPTL4, aPL) depending on eGFR in groups of RA patients without signs of metabolic syndrome and RA patients with MetS. Significant differences in the level of ANGPTL3 (F = 8.86, p = 0.0034) and ANGPTL4 (F = 29.6, p < 0.001), but not aPL (p > 0,05) were found between RA patients with varying degrees of severity of metabolic disorders.Multivariable analysis of variance showed a significant increase in ANGPTL4 in the blood serum of RA patients with reduced eGFR (< 89 ml/min) (F = 18.5, p < 0.001) and pronounced metabolic changes (F = 24.2, p < 0.001). Thus, only two factors (renal dysfunction and the presence of MetS) had a direct effect on the ANGPTL4 content in RA patients, which could describe the variability of this sign in more than 30% of cases. The squared multiple correlation coefficient (R2 ) in this model was 0.33. ANGPTL type 4 should be considered as a key factor linking the development of renal dysfunction and metabolic changes caused by rheumatoid inflammation. 


2019 ◽  
Vol 160 (44) ◽  
pp. 1727-1734
Author(s):  
László Tamási ◽  
Ágnes Miksi ◽  
Zsófia Kardos ◽  
Ágnes Flórián ◽  
Zoltán Szekanecz

Abstract: Authors discuss the musculoskeletal aspects of obesity by applying a novel approach. Biochemical changes associated with obesity and especially metabolic syndrome, may have a great impact on the function of bones, joints and muscles. Therefore we need a new view and new strategies in rheumatic diseases. Obesity-associated metabolic changes should be considered during the progress of as well as the selection of treatment in inflammatory rheumatic diseases. Individualised treatment is necessary due to associated comorbidities as well. Orv Hetil. 2019; 160(44): 1727–1734.


Sign in / Sign up

Export Citation Format

Share Document